Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: A prospective cohort study
9
lượt xem 1
download
lượt xem 1
download
Download
Vui lòng tải xuống để xem tài liệu đầy đủ
Sequential inhibition of the vascular endothelial growth factor (VEGF) pathway with sorafenib could be useful for patients with metastatic renal cell carcinoma (RCC). Our aim was to determine the activity and tolerability of sorafenib as a second-line therapy in advanced RCC initially treated with a different VEGF-tyrosine kinase inhibitor (TKI).
Chủ đề:
Bình luận(0) Đăng nhập để gửi bình luận!
CÓ THỂ BẠN MUỐN DOWNLOAD